DE602004014372D1 - N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme - Google Patents

N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Info

Publication number
DE602004014372D1
DE602004014372D1 DE602004014372T DE602004014372T DE602004014372D1 DE 602004014372 D1 DE602004014372 D1 DE 602004014372D1 DE 602004014372 T DE602004014372 T DE 602004014372T DE 602004014372 T DE602004014372 T DE 602004014372T DE 602004014372 D1 DE602004014372 D1 DE 602004014372D1
Authority
DE
Germany
Prior art keywords
noradrenaline
serotonin
pyrrolidin
inhibitors
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004014372T
Other languages
English (en)
Inventor
Paul Vincent Fish
Michael Jonathan Fray
Alan Stobie
Florian Wakenhut
Gavin WHITLOCK
Alan Daniel Brown
Mark David Andrews
David Mark
Mark Ian Lansdell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE602004014372D1 publication Critical patent/DE602004014372D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602004014372T 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme Active DE602004014372D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (1)

Publication Number Publication Date
DE602004014372D1 true DE602004014372D1 (de) 2008-07-24

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014372T Active DE602004014372D1 (de) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Country Status (31)

Country Link
US (2) US7378436B2 (de)
EP (1) EP1638933B1 (de)
JP (1) JP4137159B2 (de)
KR (1) KR100803796B1 (de)
AP (1) AP2005003467A0 (de)
AR (1) AR044715A1 (de)
AT (1) ATE398107T1 (de)
AU (1) AU2004247487B2 (de)
BR (1) BRPI0411594A (de)
CA (1) CA2530159C (de)
CY (1) CY1110434T1 (de)
DE (1) DE602004014372D1 (de)
DK (1) DK1638933T3 (de)
EA (1) EA009881B1 (de)
EC (1) ECSP056232A (de)
ES (1) ES2305776T3 (de)
HR (2) HRP20050993A2 (de)
IL (1) IL172063A0 (de)
IS (1) IS8136A (de)
MA (1) MA27885A1 (de)
MX (1) MXPA05013960A (de)
NL (1) NL1026438C2 (de)
NZ (1) NZ544046A (de)
PA (1) PA8605301A1 (de)
PE (1) PE20050631A1 (de)
PL (1) PL1638933T3 (de)
PT (1) PT1638933E (de)
SI (1) SI1638933T1 (de)
TW (1) TW200505852A (de)
UY (1) UY28360A1 (de)
WO (1) WO2004110995A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417727C (en) 2000-07-31 2009-09-01 Nycomed Danmark A/S Fentanyl composition for nasal administration
NZ544046A (en) * 2003-06-17 2009-08-28 Pfizer N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
JP5188807B2 (ja) 2004-10-18 2013-04-24 イーライ リリー アンド カンパニー ｍＧｌｕＲ３受容体アンタゴニストとして用いるための１−（ヘテロ）アリール−３−アミノ−ピロリジン誘導体
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
EP1828119A1 (de) * 2004-12-14 2007-09-05 Pfizer Limited N-pyrrolidin-3-ylamidderivate als serotonin-und noradrenalin-wiederaufnahmehemmer
CA2590229A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI439452B (zh) 2005-05-13 2014-06-01 Otsuka Pharma Co Ltd 吡咯烷化合物（二）
AU2006254256B2 (en) 2005-06-02 2012-04-12 F. Hoffmann-La Roche Ag Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
JPWO2008093737A1 (ja) * 2007-01-31 2010-05-20 大日本住友製薬株式会社 アミド誘導体
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
RU2010129690A (ru) 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные
EP2318362B1 (de) 2008-07-24 2013-09-25 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidinverbindungen
RU2503662C2 (ru) 2008-11-14 2014-01-10 Тереванс, Инк. Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010263641A1 (en) 2009-06-24 2012-01-19 Sumitomo Dainippon Pharma Co., Ltd. N-substituted-cyclic amino derivative
RU2535669C2 (ru) 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
WO2011119461A1 (en) * 2010-03-22 2011-09-29 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
CN103153950B (zh) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 血清素再摄取抑制剂
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (de)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
WO1999065881A1 (en) 1998-06-19 1999-12-23 Nissan Chemical Industries, Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
DK1311272T3 (da) 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
DE60125335T2 (de) * 2000-03-06 2007-07-12 Acadia Pharmaceuticals Inc., San Diego Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
JP2004509891A (ja) 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
JP2004509866A (ja) 2000-09-25 2004-04-02 アクテリオン　ファマシューティカルズ　リミテッド 置換アミノ−アザ−シクロアルカン
WO2003024928A2 (en) 2001-09-14 2003-03-27 Novo Nordisk A/S Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
WO2003037865A1 (en) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
IL165907A0 (en) * 2002-06-24 2006-01-15 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents
AU2003249983A1 (en) 2002-07-18 2004-02-09 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
AU2003263393A1 (en) 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CA2511242C (en) 2002-12-20 2010-01-12 Anita Melikian Inhibitors of human tumor-expressed ccxckr2
NZ544046A (en) * 2003-06-17 2009-08-28 Pfizer N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Also Published As

Publication number Publication date
WO2004110995A8 (en) 2005-04-21
AR044715A1 (es) 2005-09-21
IL172063A0 (en) 2009-02-11
JP4137159B2 (ja) 2008-08-20
EA200501730A1 (ru) 2006-08-25
KR100803796B1 (ko) 2008-02-14
AU2004247487B2 (en) 2010-05-20
WO2004110995A1 (en) 2004-12-23
CA2530159A1 (en) 2004-12-23
HRP20050993A2 (en) 2006-03-31
CY1110434T1 (el) 2015-04-29
KR20060036927A (ko) 2006-05-02
MXPA05013960A (es) 2006-02-24
PL1638933T3 (pl) 2008-10-31
UY28360A1 (es) 2005-01-31
SI1638933T1 (sl) 2008-10-31
JP2006527758A (ja) 2006-12-07
HRP20080339T3 (en) 2008-08-31
MA27885A1 (fr) 2006-05-02
EP1638933B1 (de) 2008-06-11
ES2305776T3 (es) 2008-11-01
US20080306123A1 (en) 2008-12-11
IS8136A (is) 2005-11-21
AU2004247487A1 (en) 2004-12-23
PE20050631A1 (es) 2005-09-14
BRPI0411594A (pt) 2006-08-29
EP1638933A1 (de) 2006-03-29
US7378436B2 (en) 2008-05-27
TW200505852A (en) 2005-02-16
CA2530159C (en) 2010-02-02
NL1026438A1 (nl) 2004-12-20
NZ544046A (en) 2009-08-28
ATE398107T1 (de) 2008-07-15
PT1638933E (pt) 2008-07-22
EA009881B1 (ru) 2008-04-28
DK1638933T3 (da) 2008-07-28
PA8605301A1 (es) 2005-02-04
AP2005003467A0 (en) 2006-12-31
NL1026438C2 (nl) 2005-09-20
ECSP056232A (es) 2006-04-19
US20050137229A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
DE602004014372D1 (de) N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60225162D1 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
DE502005011241D1 (de) Indazolderivate als inhibitoren der hormon-sensitiven lipase
DE60325032D1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE602006008945D1 (de) Isochinolinderivate als inhibitoren von rho-kinase
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
DK1396606T3 (da) Frakturering af underjordiske zoner
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
DE60021194D1 (de) Phenylpiperazin-derivate als inhibitoren der serotonin-wiederaufnahme
DE602004031527D1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
ATE430726T1 (de) N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b
DE602004011221D1 (de) 3-amino-pyrrolidine als inhibitoren der monoamin-wiederaufnahme
DE602004024317D1 (de) Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ATE362930T1 (de) Nicotinamid-derivate verwendbar als pde4 inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition